Search clinical trials for: SBRT combined with PD-1 inhibitors and thoracic hyperthermia

Total 1157 results

First People's Hospital of Hangzhou
Hangzhou Cancer Hospital

Recruiting

SBRT Combined With PD-1 Inhibitor and Thoracic Hyperthermia for Advanced NSCLC

Stereotactic Body Radiation Therapy; PD-1 Inhibitor; Hyperthermia; NSCLC

China
Sun Yat-sen University

Recruiting

Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC

Esophageal Squamous Cell Carcinoma | Oligometastatic Disease

China
Yongchang Zhang

Recruiting

PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC

HER2 Insertion Mutation Positive Advanced NSCLC

China
Tongji Hospital
National Natural Science Foundation of China

Recruiting

Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: a Single Center, Prospective, Open, One Arm Exploratory Clinical Study (NICCE)

Esophageal Squamous Cell Carcinoma | Neoadjuvant Therapies

China
Fudan University

Not yet recruiting

Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy

NSCLC Stage IV

China
Pengyuan Liu
Zhejiang Hospital

Completed

Hyperthermia Combined With Immune Checkpoint Inhibitor Therapy for Advanced Gastrointestinal Tumours (HEAIS001)

Gastrointestinal Tumor

China
Peking University Cancer Hospital & Institute
Innovent Biologics (Suzhou) Co. Ltd.

Completed

HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell Carcinoma

Liver Metastases | Esophageal Squamous Cell Carcinoma | Hepatic Arterial Infusion Chemotherapy

China
The Second Affiliated Hospital of Shandong First...

Recruiting

Clinical Study of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Shandong Provincial Hospital

Unknown

Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With RR NHL

Relapsed/Refractory Non-Hodgkin's Lymphoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

Immune Checkpoint Inhibitor PD-1 Antibody Combined With Chemotherapy in the Perioperative Treatment of Locally Advanced Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Locally Advanced Gastric Adenocarcinoma

China
Second Affiliated Hospital of Soochow University

Not yet recruiting

ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0)

Carcinoma | Solid Tumor

China
The First Affiliated Hospital of Guangdong Pharmaceutical...
Guangzhou Anjie Biomedical Technology Co., Ltd.

Unknown

CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer

Advanced Esophageal Cancer

China
Xiangya Hospital of Central South University
Wu Jieping Medical Foundation

Recruiting

Radiotherapy Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of NSCLC Patients With Symptomatic Brain Metastases

Non-small Cell Lung Cancer Metastatic | Brain Metastases

China
Guoxin Li

Not yet recruiting

Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer（RC48-C018）

Gastric Cancer
Shanghai Chest Hospital

Not yet recruiting

Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE) (RICE)

Chemotherapy | Immunotherapy | Concurrent Chemoradiotherapy | Esophageal Squamous Cell Carcinomas
HaEmek Medical Center, Israel

Unknown

Changes in Prostate Specific Antigen Levels During Synergo Therapy-Intravesical Chemotherapy Instillations Combined With Hyperthermia

Bladder Cancer

Israel
Henan Cancer Hospital

Active, not recruiting

Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.

HER2 Positive Metastatic Breast Cancer

China
Shandong Cancer Hospital and Institute

Recruiting

Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.

Advanced Esophageal Squamous Cell Cancer

China
Fudan University

Recruiting

SBRT for Oligo-residual NSCLC After Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors

NSCLC Stage IV

China
Sichuan Cancer Hospital and Research Institute

Recruiting

TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC

Liver Diseases | Digestive System Neoplasms | Liver Neoplasms | Hepatocellular Carcinoma | Antineoplastic Agents | Molecular Mechanisms of Pharmacological Action | Protein Kinase Inhibitors | Sorafenib

China
Tianjin Medical University Cancer Institute and...

Unknown

PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC (PLTHCC)

Hepatocellular Carcinoma Non-resectable

China
Chongqing University Cancer Hospital

Recruiting

The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC

Nasopharyngeal Carcinoma

China
Fudan University

Active, not recruiting

Multiple Target Kinase Inhibitor and Anti-Programmed Death-1 Antibody in Patients With Advanced Thyroid Cancer

Thyroid Cancer

China
Changzhou Cancer Hospital of Soochow University

Completed

An Exploration of Apatinib Combined With S-1 in Patients With Advanced Non-small Cell Lung Cancer (EASE)

Non-small Cell Lung Cancer

China
Fudan University

Recruiting

Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma

Carcinosarcoma | Sarcomatoid Carcinoma | PD-1 Immunotherapy | VEGFR-TKI

China
Shanghai Chest Hospital

Not yet recruiting

Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS) (BLESS)

Esophageal Cancer

China
First Affiliated Hospital of Guangxi Medical University

Recruiting

Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer

Cervical Cancer

China
Beijing Friendship Hospital

Recruiting

Total Neoadjuvant Therapy Combined With Tislelizumab for Local Advanced of Middle and Low Rectal Cancer

Locally Advanced Rectal Cancer

China
Beijing Friendship Hospital

Recruiting

DEP Combine With PD-1 Antibody as an Treatment for EBV-HLH

Hemophagocytic Lymphohistiocytosis

China
Shanghai First Maternity and Infant Hospital

Unknown

Programmed Death-1(PD-1) Inhibitor Combined With Progesterone Treatment in Endometrial Cancer (ECCT)

Endometrial Cancer Stage I
Fujian Cancer Hospital

Recruiting

Radiotherapy Combined With TKI and Anti-PD-1 Antibody for Stage IIIA Hepatocellular Carcinoma

Stage IIIA Hepatocellular Carcinoma

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

The Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Centipeda Minima (CM) in Lung Cancer

Lung Cancer

China
Shanghai Jiao Tong University Affiliated Sixth...

Recruiting

Neoadjuvant Chemotherapy Combined With PD-1 + Radical Radiotherapy in Locally Advanced Cervical Cancer (PD-1)

Cervical Cancer | Radiotherapy | Neoadjuvant Chemotherapy | PD-1 Antibody

China
Qingdao Central Hospital

Recruiting

Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer

Metastatic Esophageal Squamous Cell Carcinoma

China
Zhejiang Cancer Hospital

Recruiting

SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma

Biliary Tract Carcinoma

China
Xiaorong Dong

Unknown

Anlotinib In Combination With PD-1/L1 Inhibitor As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study

NSCLC | Anlotinib | PD-1/L1 Inhibitor
Fifth Affiliated Hospital, Sun Yat-Sen University

Recruiting

Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Capecitabine | Radiotherapy | PD-1 Inhibitor

China
Dong Wang

Not yet recruiting

TC Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Advanced Esophageal Cancer (TC)

ESCC

China
Hunan Cancer Hospital

Completed

Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal Cancer

Colorectal Cancer

China
Dalian University

Unknown

Treatment of Non-small Cell Lung Cancer With Cytokine-induced Killer (CIK) Cells Blocked by PD-1 Antibody

Non-small Cell Lung Cancer
Changhai Hospital

Not yet recruiting

Short-course Radiotherapy Combined With Furoquintinib and PD-1 Monoclonal Antibody (PMMR/MSS)

Rectal Cancer
Ruijin Hospital

Not yet recruiting

PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma (ENKTL)

NK-T-Cell Lymphoma, Extranodal

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Single-center, Prospective Cohort Study of PD-1 Inhibitors on Clinical Outcomes of Carotid Plaques in Tumor Patients

Carotid Artery Plaque | Pd-1 Inhibitors

China
XIANG YANQUN

Active, not recruiting

Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II Study

Chemotherapy Effect | Metastatic Nasopharyngeal Carcinoma

China
Fudan University

Recruiting

Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence (IMPROVE)

Colorectal Cancer | Liver Metastases | Radiotherapy | Immunotherapy

China
Ahmed Said Elgebaly,MD
Tanta University

Completed

Thoracic Epidural Reduces Risks of Increased Left Ventricular Mass Index During Coronary Artery Bypass Graft Surgery

Ischemia Coronary Artery Origin

Egypt
Sichuan University

Not yet recruiting

Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors

Solid Tumor
Sichuan University

Recruiting

Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.

NSCLC | PD-1 Inhibitor | Stereotactic Body Radiotherapy | Low Dose Radiotherapy

China
Peking University

Recruiting

HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT

Hepatocellular Carcinoma | Portal Vein Thrombosis

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Phase Ⅱ Clinical Study of 9MW1411 Injection in Acute Bacterial Skin and Skin Structure Infections

Skin Infection

China

3

Subscribe